These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 23408040

  • 1. Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens.
    Habib EE, Fahmy ES.
    Clin Transl Oncol; 2013 Nov; 15(11):965-8. PubMed ID: 23408040
    [Abstract] [Full Text] [Related]

  • 2. Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients.
    Shukuya T, Takahashi T, Imai H, Tokito T, Ono A, Akamatsu H, Taira T, Kenmotsu H, Naito T, Murakami H, Endo M, Yamamoto N.
    Respir Investig; 2014 Mar; 52(2):101-6. PubMed ID: 24636265
    [Abstract] [Full Text] [Related]

  • 3. Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy.
    Toyokawa G, Takenoyama M, Hirai F, Toyozawa R, Inamasu E, Kojo M, Morodomi Y, Shiraishi Y, Takenaka T, Yamaguchi M, Shimokawa M, Seto T, Ichinose Y.
    Int J Clin Oncol; 2014 Aug; 19(4):601-6. PubMed ID: 24158772
    [Abstract] [Full Text] [Related]

  • 4. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
    Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P, Maltzman JD, Wallin BA.
    Clin Cancer Res; 2014 Dec 01; 20(23):5927-36. PubMed ID: 25231400
    [Abstract] [Full Text] [Related]

  • 5. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
    Zucali PA, Ceresoli GL, Garassino I, De Vincenzo F, Cavina R, Campagnoli E, Cappuzzo F, Salamina S, Soto Parra HJ, Santoro A.
    Cancer; 2008 Apr 01; 112(7):1555-61. PubMed ID: 18286536
    [Abstract] [Full Text] [Related]

  • 6. Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study.
    Mutlu H, Gündüz S, Karaca H, Büyükçelik A, Cihan YB, Erden A, Akca Z, Coşkun HS.
    Med Oncol; 2014 Aug 01; 31(8):74. PubMed ID: 24958517
    [Abstract] [Full Text] [Related]

  • 7. Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: a mono-institutional experience.
    Pasello G, Nicotra S, Marulli G, Rea F, Bonanno L, Carli P, Magro C, Jirillo A, Favaretto A.
    Lung Cancer; 2011 Sep 01; 73(3):351-5. PubMed ID: 21296448
    [Abstract] [Full Text] [Related]

  • 8. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.
    Santoro A, O'Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, Eberhardt W, Paz-Ares L, Sundstrom S, Liu Y, Ripoche V, Blatter J, Visseren-Grul CM, Manegold C.
    J Thorac Oncol; 2008 Jul 01; 3(7):756-63. PubMed ID: 18594322
    [Abstract] [Full Text] [Related]

  • 9. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
    Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P.
    J Clin Oncol; 2003 Jul 15; 21(14):2636-44. PubMed ID: 12860938
    [Abstract] [Full Text] [Related]

  • 10. Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma.
    Berardi R, Caramanti M, Fiordoliva I, Morgese F, Savini A, Rinaldi S, Torniai M, Tiberi M, Ferrini C, Castagnani M, Rovinelli F, Onofri A, Cascinu S.
    Support Care Cancer; 2015 Mar 15; 23(3):621-6. PubMed ID: 25142706
    [Abstract] [Full Text] [Related]

  • 11. Secondline chemotherapy versus best supportive care in patient with malignant pleural mesothelioma: a retrospective study.
    Mutlu H, Buyukcelik A, Karaca H, Aksahin A, Berk V, Aslan T, Erden A, Akca Z, Ozkan M.
    Asian Pac J Cancer Prev; 2013 Mar 15; 14(6):3887-9. PubMed ID: 23886202
    [Abstract] [Full Text] [Related]

  • 12. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.
    Ceresoli GL, Aerts JG, Dziadziuszko R, Ramlau R, Cedres S, van Meerbeeck JP, Mencoboni M, Planchard D, Chella A, Crinò L, Krzakowski M, Rüssel J, Maconi A, Gianoncelli L, Grosso F.
    Lancet Oncol; 2019 Dec 15; 20(12):1702-1709. PubMed ID: 31628016
    [Abstract] [Full Text] [Related]

  • 13. [Second-line therapy in patients with malignant pleural mesothelioma. A French retrospective study (2005-2006)].
    Margery J, Rivière F, Planchard D, Le Floch H, Ferrand FR, Mairovitz A, Besse B, Vaylet F, Ruffié P.
    Rev Pneumol Clin; 2010 Sep 15; 66(4):255-9. PubMed ID: 20933167
    [Abstract] [Full Text] [Related]

  • 14. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
    Buikhuisen WA, Burgers JA, Vincent AD, Korse CM, van Klaveren RJ, Schramel FM, Pavlakis N, Nowak AK, Custers FL, Schouwink JH, Gans SJ, Groen HJ, Strankinga WF, Baas P.
    Lancet Oncol; 2013 May 15; 14(6):543-51. PubMed ID: 23583604
    [Abstract] [Full Text] [Related]

  • 15. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.
    Jänne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Ye Z, Monberg MJ, Obasaju CK, Pemetrexed expanded access program investigators.
    J Thorac Oncol; 2006 Jul 15; 1(6):506-12. PubMed ID: 17409909
    [Abstract] [Full Text] [Related]

  • 16. An unusually large pleural mesothelioma with an outstanding clinical response and long lasting survival: a case report and literature review.
    Zilembo N, Vitali M, Pietrantonio F, Platania M, Del Vecchio M, Bajetta E.
    Tumori; 2010 Jul 15; 96(6):1031-4. PubMed ID: 21388071
    [Abstract] [Full Text] [Related]

  • 17. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
    Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A, French Cooperative Thoracic Intergroup (IFCT).
    Lancet; 2016 Apr 02; 387(10026):1405-1414. PubMed ID: 26719230
    [Abstract] [Full Text] [Related]

  • 18. Pemetrexed and cisplatin for malignant pleural mesothelioma: a new standard of care?
    Rusch VW.
    J Clin Oncol; 2003 Jul 15; 21(14):2629-30. PubMed ID: 12860935
    [No Abstract] [Full Text] [Related]

  • 19. The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma.
    Ak G, Metintas S, Akarsu M, Metintas M.
    BMC Cancer; 2015 Jul 09; 15():510. PubMed ID: 26156324
    [Abstract] [Full Text] [Related]

  • 20. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.
    Simon GR, Verschraegen CF, Jänne PA, Langer CJ, Dowlati A, Gadgeel SM, Kelly K, Kalemkerian GP, Traynor AM, Peng G, Gill J, Obasaju CK, Kindler HL.
    J Clin Oncol; 2008 Jul 20; 26(21):3567-72. PubMed ID: 18640937
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.